Transitioning from the Prospective Lynch Syndrome Database (PLSD) to the International Lynch Syndrome Database (ILSD)

Lynch syndrome (LS) is an autosomal dominant predisposition to colorectal (CRC), endometrial cancer and specific other tumours, due to germline (likely) pathogenic variants in DNA mismatch repair (MMR) genes [ 1 ]. LS ranks among the most thoroughly investigated hereditary cancer syndromes, with ongoing research priorities including gene-specific cancer risks, effectiveness of surveillance protocols, patient survival, and the formulation of precision-based clinical guidelines. To address these needs, the Prospective Lynch Syndrome Database (PLSD) was launched in 2012 as an international multi-center registry designed to collect prospective follow-up data from carriers of (likely) pathogenic mismatch repair ( path_MMR ) variants) [ 2 ]. Over a decade of collaborative work on LS, PLSD has produced detailed gene‑, sex‑ and age‑specific estimates of cancer incidence, survival and surgical outcomes [ 3 , 4 ].